Calcitonin inhibits both osteoclast formation and bone resorption, and is a primary treatment for patients with hypercalcemia and increased bone turnover. However, the clinical utility of calcitonin is limited because patients become refractory to calcitonin after several days (the calcitonin "escape phenomenon"). The molecular basis for calcitonin "escape" is unclear. To determine the regulatory mechanisms controlling calcitonin receptor (CTR) expression in osteoclasts and their precursors, we treated immature mononuclear precursors for human osteoclast-like multinucleated cells (MNC) formed in vitro with 1,25-(OH)2D3, to induce their differentiation to committed mononuclear precursors, and mature multinucleated osteoclasts, and used reverse transcriptase (RT)-PCR to assess expression of CTR mRNA in both committed mononuclear precursors and MNC. The PCR fragment produced was cloned and sequenced to confirm that it was derived from CTR mRNA. CTR mRNA expression was detected in mononuclear MNC precursors after 7 d of 1,25-(OH)2D3 treatment. It was also present in osteoclast-like MNC and highly purified giant cells from osteoclastomas, but not in monocytes or macrophage polykaryons formed in vitro. Calcitonin markedly decreased CTR but not actin mRNA expression in giant cells and MNC after 12 h, and removal of calcitonin restored CTR mRNA expression. Similarly, calcitonin decreased calcitonin-induced adenylate cyclase activity. These data suggest: (a) downregulation of CTR gene expression by calcitonin may in part explain the calcitonin "escape phenomenon"; and (b) expression of CTR mRNA occurs in mononuclear osteoclast precursors within 7 d after exposure to 1,25-(OH)2D3. (J. Clin. Invest. 1995. 95:167-171.)
Introduction
Calcitonin receptor (CTR)' expression is regarded as one of the specific markers for osteoclasts that distinguish them from 1 . Abbreviations used in this paper: CTR, calcitonin receptor; MNC, multinucleated cells; RT, reverse transcriptase; TRAP, tartrate-resistant acid phosphatase. macrophage polykaryons ( 1) . High affinity CTRs have been detected in osteoclasts from animals and man (1, 2) , as well as kidney cells (3) , some carcinoma cell lines (4, 5) , and lymphocytes (6), but not on human macrophages (7) . During osteoclast differentiation, the appearance of CTR appears to parallel the capacity of mature osteoclasts to resorb bone (8, 9) . Calcitonin inhibits osteoclastic bone resorption in vitro (10, 11) , and has been used clinically to inhibit osteoclastic bone resorption in patients with the hypercalcemia of malignancy (12) (13) (14) and with Paget's disease of bone (15) . However, patients with cancer become refractory to the effects of calcitonin after several days (the calcitonin "escape phenomenon") (12, 13) . The molecular basis for calcitonin "escape" is unclear.
Recently, a human CTR cDNA from an ovarian carcinoma cell line was cloned (16), and we have used the reverse transcriptase-polymerase chain reaction (RT-PCR) and specific CTR cDNA primers to assess expression of CTR mRNA in human osteoclast-like multinucleated cells (MNC) and their mononuclear precursors to investigate the regulatory mechanisms controlling CTR expression in osteoclasts and their precursors. We previously have shown that human long-term bone marrow cultures form multinucleated cells that express an osteoclast phenotype (i.e., express CTRs, as detected by "25I-salmon calcitonin autoradiography, contract in response to calcitonin and form resorption lacunae on calcified matrices), and used them as a model for osteoclast formation (7, (17) (18) (19) (20) (21) . We have also identified immature mononuclear precursors for these MNC (7, 21) and found that treatment of these immature MNC precursors with 1,25-(OH)2D3 for 10-14 d induced expression of CTR on these mononuclear precursors. Therefore, we determined CTR mRNA expression in mononuclear MNC precursors and mature MNC and tested the capacity of calcitonin to regulate CTR mRNA expression and adenylate cyclase activity in these cells and osteoclast-like giant cells from human osteoclastomas.
Methods
Bone marrow and peripheral blood cells cultures. Cultures of immature mononuclear MNC precursors and osteoclast-like MNC were as previously described (17) (18) (19) (20) (21) . In brief, CFU-GM colonies were formed by culturing bone marrow nonadherent mononuclear cells in methylcellulose culture with 200 pg/ml recombinant human granulocyte macrophage CSF (Schering, Plough, NJ) for 7 d. The cultures were then overlaid with 1,25-(OH)2D3 10-8 M (generously provided by Dr. M. Uskokovic, Hoffman LaRoche, Nutley, NJ), and the cultures continued for 10 d. The colonies were then harvested and more differentiated mononuclear MNC precursors were isolated by immune cell panning with the 23c6 monoclonal antibody (generously provided by Dr. Horton, St. Bartholomew's Hospital, London, UK), which recognizes the vitronectin receptor on osteoclasts and their precursors (19, 22) . In selected experiments, 23c6-positive mononuclear cells were cultured in a-MEM (GIBCO BRL, Grand Island, NY)/20% FCS (Hyclone Laboratories, Logen, UT) with or without salmon calcitonin (100 ng/ml) (Rohrer, Fort Washington, PA) for the indicated times.
Downregulation of Calcitonin Receptor in Human Osteoclast-like Cells
Osteoclast-like MNC were formed by culturing bone marrow nonadherent mononuclear cells in a-MEM-20% horse serum with 10-8 M 1,25-(OH)2D3 for 3 wk. MNC were then released with chymopapain treatment (300 U/ml) (Sigma Chemical Co. St. Louis, MO) followed by gentle scraping with a rubber policeman, and then enriched by panning with the 23c6 monoclonal antibody. Macrophage polykaryons were formed as previously described ( 19) by culturing 106 peripheral blood mononuclear cells/ml in a-MEM-15% FCS with 108 M 1,25-(OH)2D3 for 3 wk. Monocytes were separated from peripheral blood mononuclear cells by adherence to plastic tissue culture dishes overnight at 370C in a-MEM-20% FCS. The adherent cell populations were > 95% monocytes by Giemsa staining.
Giant cell preparation and culture. Preparation of giant cells from osteoclastomas was as previously described (23) . Tissue samples of giant cell tumors were minced and dissociated with collagenase and hyaluronidase (Sigma Chemical Co.), passed through stainless steel wire mesh, and the cell suspension panned with the 23c6 antibody. The initial cell suspension was composed of 0.1% giant cells, and the 23c6-positive cell fraction was composed of -50% giant cells. In some selected experiments, 23c6-positive giant cells were cultured in Iscove's modified Dulbecco's medium (IMDM) -20% FCS with or without calcitonin (100 ng/ml) for the indicated times.
Isolation of RNA from pagetic bone. Pagetic bone (-2 g) was cut into small pieces and ground in liquid nitrogen using a diethylpyrocarbonate water-treated mortar and pestle. The bone material was then collected into a polypropylene tube and extracted with 5 ml RNAzol B reagent (Biotecx Laboratories, Inc., Houston, TX). The insoluble bone particles were further homogenized with a polytron tissue homogenizer for 45 s at 40C. RNA was then isolated from the bone according to the manufacturer's protocol.
Polymerase chain reaction. RNA was extracted from 103_-1O cells by the guanidinium thiocyanate-CsCl method (24) . RT-PCR was performed using a GeneAmp RNA/PCR kit (Perkin-Elmer Cetus, Norwalk, CT) with a Perkin-Elmer Cetus DNA thermal cycler according to the manufacturer's protocol for RT-PCR. Briefly, RNA primed with random primers was reverse transcribed using cloned Moloney leukemia virus reverse transcriptase (2.5 U), 1 mM of each deoxy-NTP, 50 pmol random hexamer, 1 U RNAse inhibitor in a final volume of 20 ,ul. The reaction was run at room temperature for 10 min followed by raising the temperature to 42°C for 30 min to complete the extension reaction. The reaction mixture was heated to 95°C for 5 min to denature the RNA-cDNA hybrids and quick-chilled on ice. PCR was performed with Taq DNA polymerase with 20 pmol of each primer shown below. Oligonucleotide primers for the human calcitonin receptor were synthesized on a DNA synthesizer (Applied Immune Sciences, Menlo Park, CA). The CTR sequences were: sense (1158-1178) 5'ACTGCTGGC-TGAGTGTGGAAA3', antisense (1454-1474) 5 'GAAGCAGTA-GATGGTCGCAAC3' (16), and were specific for CTR and did not react with other members of this receptor family (data not shown). The cycle profile was as follows: 45 s at 94°C for denaturation, 90 s at 64°C for annealing, and 3 min at 72°C for primer extension for 45 cycles, and finally, a 10-min extension at 72°C. PCR products were electrophoresed in 2% agarose gel and visualized using ethidium bromide. To confirm that the PCR product was derived from CTR mRNA, the product was cloned using a TA cloning kit (Invitrogen, San Diego, CA) and sequenced. For the internal controls, we used RT-PCR of tartrate-resistant acid phosphatase (TRAP) and f-actin mRNAs. These mRNAs were measured at plateau levels to confirm that the RNA in the samples was not degraded, and thus cannot be used to compare the amounts of the CTR mRNA expressed in these samples. The sequences for those primers were: TRAP, sense (97-120) 5 Adenylate cyclase assay. cAMP production was measured in intact highly purified giant cells or human osteoclast-like MNC (105 cells/ well) as previously described (27) . After culture for the indicated times, cells were washed with a-MEM three times, then incubated for 2 h with Co.). After S min, 50 rli of DMEM with or without 100 ng/ml (2 X l0-7 M) calcitonin were added to each well, and the incubations were continued for an additional 10 min. The incubations were stopped by the addition of 1 ml of trichloroacetic acid at a final concentration of 0.12 M, and then neutralized with 20 yl of 4 N NaOH. 20 yl of a carrier solution containing cAMP, adenine, adenosine, ATP, and ADP (each 5 mM) were added, followed by 2,000 cpm of 32P-cAMP to monitor cAMP recovery. Cyclic AMP was isolated by the two-column chromatographic method of Salomon et al. (28) . cAMP production was measured as counts per minute of 3H-cAMP generated from [3H]-adenine/culture well per 10-min incubation.
Statistical considerations. cAMP (3H counts/min) activity, with and without 24-h pretreatment with calcitonin, was measured in a series of five replicated experiments with three or four samples for each treatment group. Logarithms of counts were analyzed using a two-way mixedmodel analysis of variance. The model included a fixed main effect for calcitonin pretreatment and a random effect to adjust for variation in overall cAMP activity between experiments. For display, results are expressed as a proportion of the appropriate control average. Tests were performed at the 5% level of significance and analysis was carried out using SAS (V6.09; SAS Institute, Cary, NC). The cAMP activity in response to calcitonin without 24-h pretreatment with calcitonin ranged from 1,000-8,000 3H counts per minute above background for the five independent experiments.
Results
Calcitonin receptor mRNA expression in giant cell tumor of bone. Initially, we extracted RNAs from osteoclast-like giant cells from osteoclastomas and surgical bone samples of Paget's patients to determine the capacity of RT-PCR to detect expression of CTR-mRNA from these samples. RNA from 104 23c6-positive giant cells or 1 yg of RNA from pagetic bone were used for the PCR reaction. As shown in Fig. 1 , we detected a PCR product that was the predicted 317 bp long. The cloned sequence of this product showed complete identity with the predicted sequence of the human CTR cDNA (16), with only 1 bp mismatch on one of the four times it was sequenced. As a control to rule out that we were amplifying genomic DNA rather than detecting expression of CTR mRNA by PCR, we tested genomic DNA from human lymphocytes, but could not amplify the same PCR product (data not shown). Although CTR numbers are variable in these cells, Nicholson et (Fig. 2 A) . The sequence of the CTR clone derived from the MNC PCR product was identical to the predicted CTR sequence. In contrast, we could not detect CTR mRNA expression in macrophage polykaryons formed from peripheral blood mononuclear cells or monocytes (Fig. 2 A) , although all three types of cells expressed TRAP mRNA (Fig.  2 B) . The expression of TRAP mRNA in monocyte macrophages is consistent with our previous results. In contrast to murine cells, human monocyte-macrophages express TRAP within several hours after adhering to plastic (29) .
Calcitonin receptor mRNA expression in mononuclear precursors ofhuman bone marrow-derived osteoclast-like multinucleated cells. We then determined when CTR mRNA was expressed during the differentiation of osteoclast-like MNC from their immature mononuclear precursors. Immature mononuclear precursors were formed in methylcellulose cultures of human bone marrow mononuclear cells treated with rhGM-CSF for 7 d and then 1,25-(OH)2D3 was overlaid on the culture. As shown in Fig. 3 A, CTR mRNA expression was not detected in these mononuclear cells until 7 d after addition of 1,25-(OH)2D3. In contrast, TRAP mRNA was expressed in immature mononuclear precursors within 3 h after 1,25-(OH)2D3 addition (Fig.  3 B) .
Calcitonin inhibition of calcitonin receptor mRNA expression in giant cells from osteoclastomas and human MNC and their mononuclear precursors. We then used this system as a model to investigate the regulation of CTR gene expression by calcitonin in osteoclasts. We tested the effect of calcitonin ( l0-7 M) on CTR mRNA expression, because osteoclasts lose responsiveness to calcitonin after prolonged treatment ( 12, 13 ). 23c6- positive giant cells from osteoclastomas were incubated with or without calcitonin, and CTR mRNA expression was determined (Fig. 4 A) . CTR mRNA expression was not detected after 12 h of treatment with calcitonin, and the inhibition continued for at least 48 h. If the giant cells were treated with calcitonin for 24 h, then washed with media and incubated with media not containing calcitonin for an additional 24 h, CTR mRNA expression was restored. Similarly, CTR mRNA expression was decreased by calcitonin in osteoclast-like MNC, and their more differentiated precursors formed in vitro (Fig. 4 B) . CTR mRNA expression in either cells was inhibited after incubation with calcitonin for 24 h, but recovered 24 h after calcitonin was removed from the media (Fig. 4 B) .
To determine if the decrease in CTR mRNA expression was associated with decreased calcitonin receptor activity, we pretreated giant cells (Fig. 5) or marrow-derived MNC (data not shown) with calcitonin for 24 h and tested cAMP production in response to calcitonin in those cells. Pretreatment with calcitonin for 24 h significantly decreased cAMP production to -45% of control values (P < 0.00001, Fig. 5 ). The average amount of cAMP produced in response to calcitonin in cultures not pretreated with calcitonin was 634+173 fmol/105 cells plated.
Discussion
In the present study, we used RT-PCR of calcitonin receptor m.RNA to study the regulation of CTR mRNA expression in cells in the osteoclast lineage. We showed that CTR mRNA can be detected in RNA samples from osteoclast-like giant cells from osteoclastomas, and that CTR mRNA is expressed in more differentiated mononuclear MNC precursors and osteoclast-like MNC formed in vitro from human bone marrow. In contrast, CTR mRNA expression was not detected in macrophage polykaryons or peripheral blood monocytes. These data support our previous findings that these 23c6-positive MNC (31) . This phenomenon has been ascribed to secondary hyperparathyroidism (32) and formation of neutralizing antibodies to calcitonin (15) . However, in vitro cultures have shown that osteoclasts lose responsiveness to calcitonin (33) (34) (35) , and in rat bone or mouse calvaria, the inhibitory effect of calcitonin on bone resorption lasts only 48-96 h (33, 34) . In isolated osteoclasts, calcitonin induced immediate quiescence and gradual contraction of osteoclasts, as well as inhibition of bone resorption. After 4-8 h, osteoclasts regained cytoplasmic motility and resumption of bone resorption (35) . These data suggest a direct effect of calcitonin on osteoclasts.
Downregulation of CT receptors also been reported in mouse calvariae, human carcinoma cell lines, and rat kidney cells (34, (36) (37) (38) , and internalization of CTR and necessity of new protein synthesis for new receptor formation has been reported in a human breast cancer cell line (36) . However, the "escape phenomenon" cannot be explained solely on receptor internalization, because many other receptors such as the insulin receptor also are internalized (38) , and forskolin, an adenylate cyclase activator, induced similar effects in osteoclasts, including the "escape phenomenon" and inhibition of bone resorption (39) . Furthermore, inhibition of DNA synthesis in rodent organ cultures can block calcitonin escape (40) . Another possible explanation for the "escape phenomenon" is that phosphorylation of the intracellular region of the receptor results in desensitization of the intracellular signaling pathway (41) .
In the present study, we found that calcitonin treatment of osteoclast-like giant cells from osteoclastomas and osteoclastlike MNC formed in vitro, as well as mononuclear MNC precursors, for 2 12 h decreased CTR mRNA expression. These results were not due to the RNA being degraded in these samples since expression of TRAP and actin mRNA could be detected in the samples. These (42, 43) . These data suggest that hormone downregulation of 170 Takahashi et al.
A TIME (h) CALCITONIN CTR (317 bp) receptor mRNA expression may be a common mechanism that permits cells to "escape" the effects of these hormones.
